Ixia Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Ixia Plus, an angiotensin II receptor blocker combined with a thiazide diuretic, is used to manage hypertension.

• Hypertension: reduces systolic and diastolic blood pressure in patients with elevated readings.
• Essential hypertension: provides effective blood pressure control when monotherapy is insufficient.
• High blood pressure: assists in achieving target blood pressure levels as part of a comprehensive treatment plan.

• Olmesartan medoxomil selectively blocks the AT1 receptor, preventing angiotensin II from inducing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. The combined actions lower systemic vascular resistance and blood volume, resulting in decreased arterial pressure.

Ixia Plus may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: changes in potassium or sodium levels.
• Mild gastrointestinal discomfort: such as nausea or abdominal pain.

Serious or Rare Side Effects

• Severe dehydration: excessive fluid loss leading to low blood pressure.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: elevated potassium levels, potentially dangerous.
• Allergic reactions: rash, itching, or swelling.
• Angioedema: swelling of face, lips, or throat.
• Significant hypotension: markedly low blood pressure causing fainting.

Before initiating therapy with Ixia Plus, several safety considerations should be observed.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Renal function assessment: evaluate kidney function periodically.
• Electrolyte surveillance: check serum potassium and sodium regularly.
• Caution in elderly: start at lower doses due to increased sensitivity.
• Avoid in severe hepatic impairment: limited data on safety.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ixia Plus can interact with several medicines; awareness of these interactions helps maintain safety and efficacy.

Major Interactions (Avoid)

• Aliskiren: combined use may increase risk of renal dysfunction.
• Potassium‑sparing diuretics or supplements: may cause hyperkalemia.
• Lithium: increased lithium levels and toxicity.
• ACE inhibitors: additive effect on potassium and renal function.
• NSAIDs: may reduce antihypertensive effect and impair kidney function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may cause additive blood pressure lowering.
• Beta‑blockers: monitor for excessive hypotension.
• CYP450 inhibitors (e.g., ketoconazole): may increase olmesartan levels.
• Antidiabetic agents: diuretic may affect glucose control.
• Anticoagulants: monitor for changes in bleeding risk.